HRMY
Conference season: now with more biotech drama
Harmony Biosciences is lining up a presentation for its Phase 3 ARGUS trial of EPX-100, an oral investigational treatment for Dravet syndrome, at the American Academy of Neurology meeting in Chicago on April 22. The company says the poster will include open-label extension results from the ongoing study, which is still enrolling participants.
Why investors care
This is the kind of update that can quietly matter a lot. In biotech, conference presentations are often the appetizer before the main course — they can hint at whether a drug is showing enough promise to keep the market interested, or whether the story needs a lot more seasoning. If EPX-100 continues to look encouraging, that can support the pipeline narrative around a tough-to-treat rare disease.
Not just science: the C-suite shuffle
Harmony also announced a pair of leadership moves:
- Glenn Reicin is stepping in as chief financial officer
- Peter Anastasiou is moving from the board into the chief operating officer seat
Those changes matter because biotechs don’t just run on trial data; they run on cash discipline, execution, and timing. When a company is trying to turn pipeline hope into actual commercial value, having the right operators in place can be just as important as a promising poster session.
Big picture
The presentation itself is the main catalyst here, but the management additions suggest Harmony is trying to sharpen its game plan while the EPX-100 program keeps moving. Investors will be watching for whether the data looks strong enough to keep the story moving from “interesting” to “worth owning.”